HR+ Breast Cancer: 2022 Year in Review : Episode 1
Introduction to the HR+ Treatment Landscape
Virginia Kaklamani, MD and Heather McArthur, MD begin by discussing new data regarding the use of aromatase inhibitors and ovarian function suppression in women with HR+ early breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
